8-K: Pfizer Raises 2024 Guidance After Strong Second-Quarter Performance

Pfizer reported a 3% operational revenue increase in the second quarter of 2024, driven by non-COVID products, and raised its full-year revenue and adjusted EPS guidance.

Summary

• Pfizer's second-quarter 2024 revenues reached $13.3 billion, a 3% operational increase year-over-year, despite a decline in COVID-19 related revenues.
• Excluding Comirnaty and Paxlovid, revenues grew by 14% operationally.
• The company has raised its full-year 2024 revenue guidance to a range of $59.5 to $62.5 billion.
• Adjusted diluted EPS guidance for 2024 has also been raised to a range of $2.45 to $2.65.
• A manufacturing optimization program is expected to yield approximately $1.5 billion in cost savings by the end of 2027.
• Pfizer is on track to deliver at least $4 billion in net cost savings by the end of 2024 from a previously announced cost realignment program.
• Reported diluted EPS for the second quarter was $0.01, while adjusted diluted EPS was $0.60, impacted by $1.3 billion in one-time costs for the manufacturing optimization program.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the raised guidance and strong non-COVID product growth, but tempered by the significant drop in reported net income and one-time costs.

Positives

• Pfizer achieved its first quarter of topline revenue growth since the fourth quarter of 2022.
• The company's non-COVID products demonstrated strong 14% operational revenue growth.
• The updated 2024 financial guidance reflects the strong first-half performance and confidence in the business.
• The company is making progress on its cost realignment program.
• The manufacturing optimization program is expected to improve future margins.
• Several acquired products, key in-line brands, and recent commercial launches contributed to the strong performance.
• The company is reinvesting capital into research and development and returning capital to shareholders through dividends.
• The company has seen positive results from several clinical trials, including Adcetris, Elrexfio, and Lorbrena.
• The European Commission authorized the Omicron JN.1-adapted monovalent COVID-19 vaccine.
• The European Commission granted conditional marketing authorization for Durveqtix, a gene therapy for hemophilia B.

Negatives

• Reported diluted EPS for the second quarter was only $0.01, significantly impacted by one-time costs.
• The company experienced a 98% decrease in reported net income compared to the same quarter last year.
• COVID-19 vaccine revenues declined by 87% operationally.
• Xeljanz revenues decreased by 34% operationally due to prescription volume decreases and price changes.
• Ibrance revenues decreased by 8% operationally due to competitive pressure and price decreases.
• The company recorded a $1.2 billion unfavorable change in Other deductions net due to losses on equity securities and higher interest expenses.
• The effective tax rate on reported income increased due to the non-recurrence of tax benefits from the previous year.

Risks

• The company faces risks related to the outcome of research and development activities, including clinical trial results and regulatory approvals.
• There are risks associated with the commercialization of new and existing products, including competition and pricing pressures.
• The company is exposed to supply chain disruptions and manufacturing issues.
• The market for COVID-19 products is becoming more endemic and seasonal, which may reduce demand.
• The company faces risks related to intellectual property, technology, and security, including cyber-attacks.
• There are risks related to government regulations and legal proceedings, including healthcare reform and tax law changes.
• The company is exposed to general economic, political, and market conditions, including inflation and interest rate fluctuations.
• The company faces risks related to climate change and natural disasters.
• The company is exposed to risks related to restructurings and internal reorganizations.

Future Outlook

Pfizer has raised its full-year 2024 revenue guidance to a range of $59.5 to $62.5 billion and its adjusted diluted EPS guidance to a range of $2.45 to $2.65. The company expects continued growth in its non-COVID product portfolio and anticipates cost savings from its optimization programs.

Management Comments

• Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: 'We are driving progress toward our 2024 strategic priorities through solid execution across the company.'
• Dr. Bourla also noted: 'I am pleased with the strong performance of our product portfolio in the second quarter led by several of our acquired products, key in-line brands and recent commercial launches.'
• David Denton, Chief Financial Officer and Executive Vice President, stated: 'This was Pfizers first quarter of topline revenue growth, on a year-over-year basis, since the fourth quarter of 2022 when our COVID revenues peaked.'
• David Denton also stated: 'Importantly, the strong 14% operational revenue growth of our non-COVID products in the second quarter demonstrates our continued focus on commercial execution.'

Industry Context

Pfizer's results reflect a broader trend in the pharmaceutical industry of shifting focus from COVID-19 related products to other therapeutic areas. The company's emphasis on oncology and other specialty care products aligns with the industry's focus on high-growth areas. The cost-cutting measures are also in line with industry efforts to improve efficiency and profitability.

Comparison to Industry Standards

• Pfizer's 3% operational revenue growth in Q2 2024 is a positive sign, especially when compared to companies that have seen significant declines in revenue due to reduced COVID-19 product sales. For example, Moderna reported a 94% drop in COVID-19 vaccine sales in Q1 2024.
• The 14% operational growth in non-COVID products is a strong indicator of Pfizer's ability to diversify its revenue streams, which is crucial for long-term sustainability. This is comparable to companies like AbbVie, which have successfully expanded their portfolios beyond their blockbuster drugs.
• Pfizer's manufacturing optimization program, aiming for $1.5 billion in savings by 2027, is similar to cost-cutting initiatives seen across the pharmaceutical industry, such as Novartis's restructuring program aimed at saving $1.5 billion by 2024.
• The company's adjusted diluted EPS guidance of $2.45 to $2.65 for 2024 is a positive signal to investors, indicating confidence in future profitability. This is in line with the industry average for large pharmaceutical companies, which typically aim for EPS growth in the mid-single digits.
• The 71% operational growth in Vyndaqel family revenues highlights the success of Pfizer's specialty care portfolio, which is a key area of focus for many large pharmaceutical companies. This growth is comparable to the success of other specialty drugs in the market, such as Regeneron's Dupixent.
• The 44% operational growth in Nurtec ODT/Vydura revenues demonstrates the potential of new product launches to drive growth, which is a common strategy in the pharmaceutical industry. This is similar to the success of other recently launched drugs, such as Eli Lilly's Mounjaro.

Management Changes

Legal Proceedings

• The company is facing certain product liability expenses related to products discontinued and/or divested by Pfizer.

Stakeholder Impact

• Shareholders will benefit from increased dividends and potential share repurchases.
• Employees may be affected by the cost realignment and manufacturing optimization programs, including potential job losses.
• Customers will benefit from the continued development and availability of new and existing products.
• Suppliers may be impacted by changes in the company's manufacturing and supply chain operations.
• Creditors may be impacted by changes in the company's financial performance and capital allocation.

Next Steps

• Pfizer plans to conduct dose optimization studies for danuglipron in the second half of 2024.
• The company will discuss the positive results from the AFFINE study for giroctocogene fitelparvovec with regulatory authorities.
• Pfizer will continue to monitor developments regarding the circulation and outbreaks of the A/H5N1 virus.
• The company will continue to progress its cost realignment program and manufacturing optimization program.

Key Dates

Keywords

Pfizer, Financial Results, Revenue Growth, EPS Guidance, Manufacturing Optimization, Cost Savings, Oncology, COVID-19, Pharmaceuticals, Biopharma